Finoriq research workspace
Acurx Pharmaceuticals, Inc. (ACXP) SEC Filings & Filing Highlights
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to. Review ACXP SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
- Company
- Acurx Pharmaceuticals, Inc. (ACXP)
- Ticker
- ACXP
- Market Cap
- $6.5M
- Latest Price
- $1.52
- Industry
- Biotech & Pharma
Acurx Pharmaceuticals, Inc. (ACXP) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Acurx Pharmaceuticals, Inc. (ACXP).
| Event | Form | Date |
|---|---|---|
| Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-T...Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | 8-K8.01 | 2026-04-16 |
| Acurx Pharmaceuticals, Inc.: Securities issuanceAcurx Pharmaceuticals, Inc. filed a Form 8-K covering securities issuance | 8-K3.02 | 2026-04-16 |
| Acurx Pharmaceuticals, Inc.: Material agreementOn April 15, 2026, Acurx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “... | 8-K1.01 | 2026-04-16 |
| Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has...Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm | 8-K8.01 | 2026-03-09 |
| On March 9, 2026, the Compensation Committee of the Board of Directors (the “Compensation Commi...On March 9, 2026, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of Acurx Pharmaceuticals, Inc. (the “... | 8-K5.02 | 2026-03-09 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.